$100 Billion by 2030: The Condition-Specific Market Potential In Women’s Health
Capitalizing on a Market Primed for Growth
Powered By The WHAM® Report
Certain disease areas illustrate the outsized commercial potential of women’s health. These categories combine large patient populations, documented diagnostic and treatment gaps, and accelerating market forecasts, conditions that signal strong demand and underpenetrated markets. Some examples include:
Conditions That Affect Women Differently
Cardiovascular Disease: Cardiovascular disease is the leading cause of death for U.S. women. With 45% of U.S. women having some form of CVD yet remaining under-diagnosed, the market for women-specific cardiac care could reach approximately $20 billion by 2030.27 Even for cardiovascular conditions with similar prevalence by sex or higher prevalence for men, substantial sex-based differences are evident in outcomes.
Women are 50% more likely to die following a heart attack, and are at greater risk of death, stroke, and hospital readmission. Even in conditions where prevalence is similar across sexes, outcomes differ sharply, signaling a major opportunity for differentiated diagnostics and therapeutics.
Mental Health: Mental health conditions affect women differently, with meaningful differences in symptom presentation, risk periods, and treatment responses. Even where prevalence may be similar across sexes, biological factors—including hormonal transitions across the menstrual cycle, pregnancy, and menopause—shape disease course and outcomes in ways current diagnostic frameworks and trials do not capture.
The global mental health care market reached $448 billion in 2024 and is projected to grow to $573 billion by 2033, signaling a clear opportunity for scalable, differentiated solutions tailored to women’s health.
Conditions That Affect Women Disproportionately
Alzheimer’s Disease: Women represent two-thirds of Alzheimer’s patients, and roughly one-third go undiagnosed. If diagnostic delays in women were reduced, it is estimated the treatment market could expand to more than $20 billion by 2030.
Importantly, this prevalence difference is not solely attributable to longevity differences by sex, reinforcing a critical biological and clinical opportunity.
Autoimmune Diseases: Women represent 80% of autoimmune disease patients, including conditions like rheumatoid arthritis (affecting 70% women), lupus (affecting nine women for every man), and Sjögren’s syndrome (affecting 19 women for every man).
Recent analysis projects the autoimmune market growing from $110.5B in 2025 to $144.3B in 2035, reflecting high unmet need and therapeutic expansion.
Osteoporosis: The osteoporosis market could grow from $5 billion today to $21–27 billion by 2030, driven by improved screening and diagnostics.
Despite women comprising 80% of osteoporosis patients, two-thirds remain undiagnosed, underscoring major gaps in detection and treatment pathways.
Conditions That Affect Women Exclusively
Endometriosis: Endometriosis affects 1 in 10 women globally, approximately 190 million women, yet diagnostic delays average 7-10 years. With virtually no non-invasive diagnostics and limited treatment options, the global market is projected to grow from $1.4 billion in 2023 to $2.3 billion by 2030.
The U.S. economic burden of this condition exceeds $78 billion annually through healthcare costs and lost productivity, highlighting the scale of the opportunity for improved diagnostics and therapeutics.
Menopause: The U.S. menopause market alone could grow from ~$5 billion today to $40 billion by 2030, an eight-fold increase. Yet only ~25% of women with menopausal symptoms currently seek treatment, despite the fact that more than half of the world’s population will experience menopause.
Perimenopause can begin in the late 30s, with most women experiencing menopause between ages 45 and 56, prime working years, followed by post-menopausal health needs, representing one of the most untapped and enduring markets in healthcare.
Collectively, these conditions represent a $100+ billion market opportunity in the U.S. by decade’s end, and they represent only a fraction of the conditions where women experience diagnostic delays, treatment gaps, or biologically distinct disease pathways. This represents a multi-category, multi-decade growth opportunity for investors and companies positioned to lead in sex-differentiated care.
